DelSiTech Ltd Receives Significant Funding for Developing Long-Acting Injectables

for contraceptives and HIV antivirals development

by the Bill & Melinda Gates Foundation


Turku, Finland – 21 May 2019: DelSiTech Ltd, a Finnish drug delivery and drug development company, today announced significant grant funding to support the development of long-acting controlled release formulations for family planning as well as for human immunodeficiency virus (HIV) antivirals, from the Bill & Melinda Gates Foundation.

DelSiTech is the global leader in advanced silica-based, sustained and controlled release delivery technologies for administration of injectable, implant and topical eye drop dosage forms. Its technology offers long-acting injectable medical solutions to enable longer treatment periods and fewer injections.

Dr. Lasse Leino, CEO of DelSiTech, said: “In low- and middle-income countries, there are still tens of millions of women who need support for family planning, and individuals at risk of HIV infection in need of better prevention measures. DelSiTech’s mission is to use our technology to develop novel products that bring the life-altering relief, to those in most need. This grant will be used to provide long lasting and safe contraception for women, and for the development of long acting HIV therapy in order to overcome adherence issues. We are proud to be working on innovative solutions for these underserved populations with the support of the Bill & Melinda Gates Foundation”.

DelSiTechTM Silica Matrix technology allows the drug substances, ranging from small molecules to biologics to be encapsulated in matrix microparticles, providing stability for the drug substance and a true controlled long-acting release based on the matrix’ dissolution. This allows the injection to release a stabilized product for months or over a year.

The announcement marks the strengthening of DelSiTech’s alliance with the Bill & Melinda Gates Foundation and a renewed commitment by both parties to relieve underserved patients globally.


Media enquiries: Optimum Strategic Communications, Mary Clark, Hollie Vile, Ellie Blackwell, Tel: +44 (0) 203 9509144,